While the concept of informed consent it a good one, there is a fundamental problem with the informed consent and how it is practiced today, writes Harlan Krumholz, MD, SM, professor of cardiology, epidemiology, and public health.
While the concept of informed consent it a good one, there is a fundamental problem with the informed consent and how it is practiced today, Harlan Krumholz, MD, SM, professor of cardiology, epidemiology, and public health at the Yale University School of Medicine and director of the Yale-New Haven Hospital Center for Outcomes Research and Evaluation, wrote in MedPage Today.
Ideally, through informed consent patients would learn about the risks and benefits of a treatment and alternatives, which could include doing nothing. Instead, the concept has "devolved into a perfunctory exercise by medical personnel to ensure that the 'chart' has the proper paperwork," he wrote.
Instead of being customized, consent forms are commonly standardized documents that require health literacy far exceeding the capability of th patient. In addition, they are often not well or rested enough to take the time to truly understand what is being presented to them.
Read the full article at MedPage Today: http://bit.ly/1Bu2MOD
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
Bustling Gene Therapy Pipeline for Neuromuscular Diseases Brings Thorny Questions to the Clinic
March 18th 2025The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but also logistical hurdles and a need for complex discussions between clinicians and families.
Read More